Susquehanna International Group LLP reduced its position in Ingevity Corporation (NYSE:NGVT - Free Report) by 74.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,879 shares of the company's stock after selling 42,731 shares during the period. Susquehanna International Group LLP's holdings in Ingevity were worth $1,111,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of the company. Los Angeles Capital Management LLC lifted its position in Ingevity by 94.2% during the fourth quarter. Los Angeles Capital Management LLC now owns 30,877 shares of the company's stock valued at $1,827,000 after buying an additional 14,975 shares in the last quarter. Pacer Advisors Inc. purchased a new position in shares of Ingevity in the 4th quarter valued at $9,660,000. Principal Financial Group Inc. lifted its holdings in shares of Ingevity by 4.0% during the 1st quarter. Principal Financial Group Inc. now owns 678,037 shares of the company's stock valued at $48,297,000 after acquiring an additional 25,800 shares in the last quarter. Bessemer Group Inc. boosted its position in Ingevity by 465.9% during the 1st quarter. Bessemer Group Inc. now owns 314,739 shares of the company's stock worth $22,419,000 after purchasing an additional 259,124 shares during the period. Finally, Illinois Municipal Retirement Fund acquired a new stake in Ingevity in the 1st quarter valued at $1,465,000. Hedge funds and other institutional investors own 91.59% of the company's stock.
Ingevity Stock Performance
Ingevity stock opened at $69.35 on Monday. Ingevity Corporation has a 12-month low of $45.85 and a 12-month high of $79.29. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of 47.18 and a beta of 1.16. The company has a debt-to-equity ratio of 22.52, a current ratio of 1.61 and a quick ratio of 1.15. The firm's fifty day moving average price is $73.53 and its 200 day moving average price is $71.79.
Ingevity (NYSE:NGVT - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The company reported $1.74 earnings per share for the quarter, beating analysts' consensus estimates of $1.33 by $0.41. The company had revenue of $314.10 million during the quarter, compared to analysts' expectations of $312.20 million. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. On average, research analysts forecast that Ingevity Corporation will post 5.4 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
NGVT has been the subject of several analyst reports. Wall Street Zen downgraded Ingevity from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 1st. Weiss Ratings upgraded Ingevity from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday, July 31st. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Ingevity presently has an average rating of "Hold" and an average price target of $80.00.
View Our Latest Research Report on Ingevity
Insider Transactions at Ingevity
In other Ingevity news, SVP Ryan C. Fisher sold 2,709 shares of Ingevity stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $73.72, for a total transaction of $199,707.48. Following the sale, the senior vice president directly owned 15,722 shares in the company, valued at $1,159,025.84. The trade was a 14.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David H. Li sold 5,000 shares of the company's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $75.83, for a total value of $379,150.00. Following the completion of the transaction, the chief executive officer directly owned 120,636 shares in the company, valued at approximately $9,147,827.88. The trade was a 3.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 17,801 shares of company stock valued at $1,347,481 in the last three months. 0.88% of the stock is currently owned by company insiders.
Ingevity Profile
(
Free Report)
Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.
The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.
Further Reading
Want to see what other hedge funds are holding NGVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ingevity Corporation (NYSE:NGVT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ingevity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ingevity wasn't on the list.
While Ingevity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.